Drug intelligence / Profile preview

nelarabine

Development stage
Approved
Lead developer
Shorla Oncology
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration
Intravenous
01

Overview

Nelarabine is a small molecule prodrug of the nucleotide metabolism inhibitor deoxyguanosine analogue 9-β-arabinoguanine (ARA-G). It is converted to its active form, ARA-GTP, through catalytic transformation by adenosine deaminase (ADA) and subsequent phosphorylation by deoxyguanosine kinase and deoxycytosine nucleoside kinase. ARA-GTP accumulates within leukemic blast cells, where it binds to deoxyribonucleic acid (DNA), effectively inhibiting DNA synthesis and ultimately leading to cell death. Nelarabine is a T-cell specific purine nucleoside analogue and is approved for the treatment of relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL).

Brand names
ArranonArranon GSH-111SH111SH 111
Other names
nelarabine injectionara-G9-β-arabinoguanine
02

Targets

LIG1 (DNA ligase 1)POLA1 (DNA polymerase alpha)DNA polymerase alpha-primase complex interface with Minichromosome maintenance protein 10 (MCM10) and WD repeat and HMG-box DNA-binding protein 1 (WDHD1)POLB (DNA polymerase beta)POLD1 (DNA polymerase delta)POLE (DNA polymerase epsilon)POLG (Mitochondrial DNA polymerase gamma)DNA-directed primase/polymerase protein (PrimPol)RRM1DNA

Beyond the preview

Go deeper on nelarabine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on nelarabine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call